Loading
A phase 1/2 trial of Obinutuzumab, Pembrolizumab in melanoma and renal cell carcinoma, run by Simcha IL-18, Inc., now recruiting.
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 is a phase 1/2 interventional study registered as NCT04787042 by Simcha IL-18, Inc., with 316 participants planned, started 2021-08-06 and due to reach its primary completion in 2025-06-30. Interventions recorded: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab. Conditions listed: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies.
Shares Obinutuzumab, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/